Brand-to-generic Levetiracetam Switch in Patients with Epilepsy: Seizure Control and its Predictors in a Real-world Setting

Siriporn Tiamkao; Natthawaree Kanchanauthai; Kittisak Sawanyawisuth; Somsak Tiamkao

doi:10.3889/oamjms.2022.8837

Authors

Siriporn Tiamkao Department of Pharmacology, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand; Integrated Epilepsy Research Group, Khon Kaen University, Khon Kaen, Thailand
Natthawaree Kanchanauthai Department of Medicine, Phra Nang Klao Hospital, Nonthaburi, Thailand
Kittisak Sawanyawisuth Departrment of Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand
Somsak Tiamkao Integrated Epilepsy Research Group, Khon Kaen University, Khon Kaen, Thailand; Departrment of Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand https://orcid.org/0000-0001-5178-478X

DOI:

https://doi.org/10.3889/oamjms.2022.8837

Keywords:

Seizure control, Predictors, Seizure frequency

Abstract

BACKGROUND: Epilepsy is a common neurological disease. Treatment with original antiepileptic drugs may result in high cost. Levetiracetam (LEV) is a broad-spectrum antiepileptic drug. Several studies showed that generic LEV is safe, effective, and saves cost. There are limited data on predictors of seizure control in persons with epilepsy treated with LEV, particularly switch therapy to generic LEV.

METHODS: This study was a comparison study conducted at two tertiary care hospitals. One hospital used an original LEV, while another one switched to generic LEV. The outcomes of the study included seizure control after switching to generic LEV treatment, treatment cost, dosage of LEV, adverse events of LEV, switching therapy to original LEV, emergency room visit, and abnormal laboratory tests. These outcomes were compared between the generic and original LEV. Seizure control defined by free of seizure after switch therapy. Predictors of seizure control were analyzed by multiple logistic regression analysis.

RESULTS: During the study period, there were 96 eligible patients and treated with generic LEV in 61 patients (63.54%). Regarding treatment outcomes, the generic LEV group had significantly higher proportions of seizure control (91.80% vs. 45.71%) than the original LEV group. The original LEV group had significantly higher cost than the generic LEV group (65,250 vs. 9500 Baht; p < 0.001). The final model had two factors remaining: Generic LEV and frequency of seizure before switch therapy. Generic LEV was independently associated with seizure control with adjusted OR of 6.35 (95% CI of 1.73, 23.34).

CONCLUSION: Switch therapy to generic LEV is an alternative therapy with comparable efficacy, lower cost, and safe. Generic LEV and frequency of seizure attack before switch therapy to generic LEV may be related to seizure control.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Beghi E. The epidemiology of epilepsy. Neuroepidemiology. 2020;54(2):185-91. https://doi.org/10.1159/000503831 PMid:31852003 DOI: https://doi.org/10.1159/000503831

Webb CA, Wanbon R, Otto ED. Levetiracetam for status epilepticus in adults: A systematic review. Can J Hosp Pharm. 2022;75(1):46-53. https://doi.org/10.4212/cjhp.v75i1.3254 PMid:34987263 DOI: https://doi.org/10.4212/cjhp.v75i1.3254

Wongjirattikarn R, Sawanyawisuth K, Pranboon S, Tiamkao S, Tiamkao S. Can generic intravenous levetiracetam be used for acute repetitive convulsive seizure or status epilepticus? A randomized controlled trial. Neurol Ther. 2019;8(2):425-31. https://doi.org/10.1007/s40120-019-00150-x PMid:31407191 DOI: https://doi.org/10.1007/s40120-019-00150-x

Delanty N, Jones J, Tonner F. Adjunctive levetiracetam in children, adolescents, and adults with primary generalized seizures: open-label, noncomparative, multicenter, long-term follow-up study. Epilepsia. 2012 Jan;53(1):111-9. https://doi.org/10.1111/j.1528-1167.2011.03300.x PMid:22050371 DOI: https://doi.org/10.1111/j.1528-1167.2011.03300.x

Johansen ME, Richardson C. Estimation of potential savings through therapeutic substitution. JAMA Intern Med. 2016;176(6):769-75. https://doi.org/10.1001/jamainternmed.2016.1704 PMid:27159226 DOI: https://doi.org/10.1001/jamainternmed.2016.1704

Gha-Hyun L, Dae SJ. Brand name to generic substitution of levetiracetam in patients with epilepsy. Seizure. 2018;60:127-31. https://doi.org/10.1016/j.seizure.2018.06.020 PMid:29960217 DOI: https://doi.org/10.1016/j.seizure.2018.06.020

Trimboli M, Russo E, Mumoli L, Tripepi G, Fortunato F, Mastroianni G, et al. Brand-to-generic levetiracetam switching: A 4-year prospective observational real-life study. Eur J Neurol. 2018;25(4):666-71. https://doi.org/10.1111/ene.13568 PMid:29322654 DOI: https://doi.org/10.1111/ene.13568

Bosak M, Słowik A, Turaj W. Safety of switching from brand-name to generic levetiracetam in patients with epilepsy. Drug Des Devel Ther. 2017;11:2287-91. https://doi.org/10.2147/dddt.s138270 PMid:28814836 DOI: https://doi.org/10.2147/DDDT.S138270

Olsson P, Reimers A, Källén K. Quality of life after switching to generic levetiracetam-A prospective comparative study. Epilepsy Behav. 2019;96:169-74. https://doi.org/10.1016/j.yebeh.2019.04.029 PMid:31150996 DOI: https://doi.org/10.1016/j.yebeh.2019.04.029

Markoula S, Chatzistefanidis D, Gatzonis S, Siatouni A, Siarava E, Verentzioti A, et al. Brand-to-generic levetiracetam switch in patients with epilepsy in a routine clinical setting. Seizure. 2017;48:1-6. https://doi.org/10.1016/j.seizure.2017.03.012 PMid:28363098 DOI: https://doi.org/10.1016/j.seizure.2017.03.012

Fanella M, Morano A, Fattouch J, Albini M, Basili LM, Casciato S, et al. Switch from originator to equivalent drug in the era of generic antiepileptic drugs: Study of keppra versus epitiram clinical equivalence. Clin Neuropharmacol. 2017;40(6):239-42. https://doi.org/10.1097/wnf.0000000000000250 PMid:28976412 DOI: https://doi.org/10.1097/WNF.0000000000000250

Contin M, Alberghini L, Candela C, Benini G, Riva R. Intrapatient variation in antiepileptic drug plasma concentration after generic substitution vs stable brand-name drug regimens. Epilepsy Res. 2016;122:79-83. https://doi.org/10.1016/j.eplepsyres.2016.02.012 PMid:26987080 DOI: https://doi.org/10.1016/j.eplepsyres.2016.02.012

Reimers A, Olsson P, Nilsson J, Hoff E, Reis M, Strandberg M, et al. Impact of generic substitution on levetiracetam serum concentration-A prospective study in an outpatient setting. Epilepsy Res. 2017;134:54-61. https://doi.org/10.1016/j.eplepsyres.2017.04.017 PMid:28595756 DOI: https://doi.org/10.1016/j.eplepsyres.2017.04.017

Fitzgerald CL, Jacobson MP. Generic substitution of levetiracetam resulting in increased incidence of breakthrough seizures. Ann Pharmacother. 2011;45(5):e27. https://doi.org/10.1345/aph.1p765 PMid:21521860 DOI: https://doi.org/10.1345/aph.1P765

Chaluvadi S, Chiang S, Tran L, Goldsmith CE, Friedman DE. Clinical experience with generic levetiracetam in people with epilepsy. Epilepsia. 2011;52(4):810-5. https://doi.org/10.1111/j.1528-1167.2011.03025.x PMid:21426334 DOI: https://doi.org/10.1111/j.1528-1167.2011.03025.x